Chiappori AA, Creelan B, Tanvetyanon T, Gray JE, et al. Phase I study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab, in patients with advanced non-small cell lung cancer. Clin Cancer Res 2022 Mar 7. pii: 682078. doi: 10.1158/1078-0432.CCR-21-2742.
PMID: 35254415